CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moos, P. J.
Right arrow Articles by Fitzpatrick, F. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moos, P. J.
Right arrow Articles by Fitzpatrick, F. A.

Cell Growth & Differentiation, Vol 9, Issue 8 687-697, Copyright © 1998 by American Association of Cancer Research


ARTICLES

Taxanes propagate apoptosis via two cell populations with distinctive cytological and molecular traits

PJ Moos and FA Fitzpatrick
Department of Oncological Science, Huntsman Cancer Institute, University of Utah, Salt Lake City 84112, USA.

Taxol and Taxotere propagate apoptosis in Jurkat T cells via molecular signals that coincide with the appearance of two distinct cell populations. Cell cycle arrest in G2-M phase and activation of cell cycle-dependent kinases begin within 2 h and extend to most cells by 16 h. Phosphorylation of Bcl-2 also begins within 2 h and intensifies from 2-16 h. Cell cycle arrest, activation of mitotic kinases, and phosphorylation of Bcl-2 coincided with the appearance of a population of metastable cells that accumulate YO-PRO-1 dye, are resistant to the caspase inhibitor carbobenzoxy-L-aspartyl-alpha-[(2,6-dichlorobenzoyl)oxy]methane, and have intact genomic DNA. Phosphorylation and deactivation of kinases that relay survival/mitogenesis signals in T cells begin after 8 h and are prominent by 12-16 h. Deactivated kinases include c-Raf-1, p44 extracellular receptor kinase, and the tyrosine kinases c-Lck and ZAP-70. Activation of Mr 40,000 and Mr 52,000 kinases is also prominent by 12-16 h. The modulation of all these kinases coincided with the activation of caspase-3 at 12 h and the appearance of a population of apoptotic cells that accumulate YO-PRO-1, are susceptible to the caspase inhibitor carbobenzoxy-L-aspartyl-alpha-[(2,6-dichloro-benzoyl)oxy]methane, and contain fragmented genomic DNA. This distinctive apoptosis signaling pathway may help account for the superior cytotoxic efficacy of taxanes in certain types of cancer.


This article has been cited by other articles:


Home page
Toxicol SciHome page
H. Ellinger-Ziegelbauer, J. M. Fostel, C. Aruga, D. Bauer, E. Boitier, S. Deng, D. Dickinson, A.-C. Le Fevre, A. J. Fornace Jr, O. Grenet, et al.
Characterization and Interlaboratory Comparison of a Gene Expression Signature for Differentiating Genotoxic Mechanisms
Toxicol. Sci., August 1, 2009; 110(2): 341 - 352.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
P. B. Cassidy, K. Edes, C. C. Nelson, K. Parsawar, F.A. Fitzpatrick, and P. J. Moos
Thioredoxin reductase is required for the inactivation of tumor suppressor p53 and for apoptosis induced by endogenous electrophiles
Carcinogenesis, December 1, 2006; 27(12): 2538 - 2549.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. E. Winters, A. I. Mehta, E. F. Petricoin III, E. C. Kohn, and L. A. Liotta
Supra-additive Growth Inhibition by a Celecoxib Analogue and Carboxyamido-triazole Is Primarily Mediated through Apoptosis
Cancer Res., May 1, 2005; 65(9): 3853 - 3860.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
T.T.T. Nguyen, E. Tran, T.H. Nguyen, P.T. Do, T.H. Huynh, and H. Huynh
The role of activated MEK-ERK pathway in quercetin-induced growth inhibition and apoptosis in A549 lung cancer cells
Carcinogenesis, May 1, 2004; 25(5): 647 - 659.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
F. C. Holsinger, D. D. Doan, S. A. Jasser, E. A. Swan, J. S. Greenberg, B. A. Schiff, B. N. Bekele, M. N. Younes, C. D. Bucana, I. J. Fidler, et al.
Epidermal Growth Factor Receptor Blockade Potentiates Apoptosis Mediated by Paclitaxel and Leads to Prolonged Survival in a Murine Model of Oral Cancer
Clin. Cancer Res., August 1, 2003; 9(8): 3183 - 3189.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Mo, Y. Gan, S. Song, J. Johnston, X. Xiao, M. G. Wientjes, and J. L-S. Au
Simultaneous Targeting of Telomeres and Telomerase as a Cancer Therapeutic Approach
Cancer Res., February 1, 2003; 63(3): 579 - 585.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
P. J. Moos, K. Edes, P. Cassidy, E. Massuda, and F. A. Fitzpatrick
Electrophilic Prostaglandins and Lipid Aldehydes Repress Redox-sensitive Transcription Factors p53 and Hypoxia-inducible Factor by Impairing the Selenoprotein Thioredoxin Reductase
J. Biol. Chem., January 10, 2003; 278(2): 745 - 750.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
B. S. Cummings and R. G. Schnellmann
Cisplatin-Induced Renal Cell Apoptosis: Caspase 3-Dependent and -Independent Pathways
J. Pharmacol. Exp. Ther., July 1, 2002; 302(1): 8 - 17.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J.-G. Chen and S. B. Horwitz
Differential Mitotic Responses to Microtubule-stabilizing and -destabilizing Drugs
Cancer Res., April 1, 2002; 62(7): 1935 - 1938.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
J. E. Mullally, P. J. Moos, K. Edes, and F. A. Fitzpatrick
Cyclopentenone Prostaglandins of the J Series Inhibit the Ubiquitin Isopeptidase Activity of the Proteasome Pathway
J. Biol. Chem., August 10, 2001; 276(32): 30366 - 30373.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
D. I. Rosenthal, J. H. Lee, R. Sinard, D. A. Yardley, M. Machtay, D. M. Rosen, M. J. Egorin, R. S. Weber, G. S. Weinstein, A. A. Chalian, et al.
Phase I Study of Paclitaxel Given by Seven-Week Continuous Infusion Concurrent With Radiation Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
J. Clin. Oncol., March 1, 2001; 19(5): 1363 - 1373.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
W. F. Symmans, M. D. Volm, R. L. Shapiro, A. B. Perkins, A. Y. Kim, S. Demaria, H. T. Yee, H. McMullen, R. Oratz, P. Klein, et al.
Paclitaxel-induced Apoptosis and Mitotic Arrest Assessed by Serial Fine-Needle Aspiration: Implications for Early Prediction of Breast Cancer Response to Neoadjuvant Treatment
Clin. Cancer Res., December 1, 2000; 6(12): 4610 - 4617.
[Abstract] [Full Text]


Home page
Proc. Natl. Acad. Sci. USAHome page
P. J. Moos, K. Edes, and F. A. Fitzpatrick
Inactivation of wild-type p53 tumor suppressor by electrophilic prostaglandins
PNAS, August 1, 2000; 97(16): 9215 - 9220.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
J.-i. Okano and A. K. Rustgi
Paclitaxel Induces Prolonged Activation of the Ras/MEK/ERK Pathway Independently of Activating the Programmed Cell Death Machinery
J. Biol. Chem., May 25, 2001; 276(22): 19555 - 19564.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
J. E. Mullally, P. J. Moos, K. Edes, and F. A. Fitzpatrick
Cyclopentenone Prostaglandins of the J Series Inhibit the Ubiquitin Isopeptidase Activity of the Proteasome Pathway
J. Biol. Chem., August 10, 2001; 276(32): 30366 - 30373.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
P. J. Moos, K. Edes, and F. A. Fitzpatrick
Inactivation of wild-type p53 tumor suppressor by electrophilic prostaglandins
PNAS, August 1, 2000; 97(16): 9215 - 9220.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 1998 by the American Association of Cancer Research.